{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:50:56Z","timestamp":1772794256560,"version":"3.50.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Imatinib mesylate, a tyrosine kinase inhibitor targeting bcr-abl, platelet-derived growth factor receptor (PDGF-R), and c-Kit, effectively induces hematologic and cytogenetic remissions in bcr-abl+ chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) with only mild to moderate side effects. Here, we describe the successful treatment of a 64-year-old man with c-Kit+ secondary acute myeloid leukemia (AML) refractory to standard chemotherapy. Upon 2 weeks of imatinib mesylate administration, the patient achieved a complete hematologic remission in peripheral blood. In addition, complete clearance of leukemic blasts in bone marrow and a significant cytogenetic response lasting for more than 5 months was observed. Sequence analysis of exons 2, 8, 10, 11, and 17 of the c-Kit receptor did not reveal structural alterations as previously described in a subset of AML cases. This is the first report of complete remission achieved upon administration of imatinib mesylate in a patient with highly refractory, secondary AML.<\/jats:p>","DOI":"10.1182\/blood-2002-05-1469","type":"journal-article","created":{"date-parts":[[2003,4,2]],"date-time":"2003-04-02T18:43:59Z","timestamp":1049309039000},"page":"2960-2962","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML"],"prefix":"10.1182","volume":"101","author":[{"given":"Thomas","family":"Kindler","sequence":"first","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Breitenbuecher","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Marx","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Hess","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Gschaidmeier","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinold","family":"Gamm","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles J.","family":"Kirkpatrick","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Huber","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fischer","sequence":"additional","affiliation":[{"name":"From the Johannes Gutenberg University, Department of Hematology\/Oncology and Department of Pathology, Mainz, Germany; Novartis Pharma, Nuremberg, Germany."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111616403470900_B1","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1177\/42.11.7523489","article-title":"Expression of c-kit and kit ligand proteins in normal human tissues.","volume":"42","author":"Lammie","year":"1994","journal-title":"J Histochem Cytochem."},{"key":"2019111616403470900_B2","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/352809a0","article-title":"Requirement for mast cell growth factor for primordial germ cell survival in culture.","volume":"352","author":"Dolci","year":"1991","journal-title":"Nature."},{"key":"2019111616403470900_B3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/373347a0","article-title":"W\/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity.","volume":"373","author":"Huizinga","year":"1995","journal-title":"Nature."},{"key":"2019111616403470900_B4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.174.1.63","article-title":"Expression and function of c-kit in hemopoietic progenitor cells.","volume":"174","author":"Ogawa","year":"1991","journal-title":"J Exp Med."},{"key":"2019111616403470900_B5","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","article-title":"Early signaling pathways activated by c-Kit in hematopoietic cells.","volume":"31","author":"Linnekin","year":"1999","journal-title":"Int J Biochem Cell Biol."},{"key":"2019111616403470900_B6","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111616403470900_B7","first-page":"2291","article-title":"Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer.","volume":"6","author":"Hibi","year":"1991","journal-title":"Oncogene."},{"key":"2019111616403470900_B8","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.","volume":"279","author":"Hirota","year":"1998","journal-title":"Science."},{"key":"2019111616403470900_B9","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood.V78.11.2962.2962","article-title":"Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells.","volume":"78","author":"Ikeda","year":"1991","journal-title":"Blood."},{"key":"2019111616403470900_B10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood.V80.1.60.60","article-title":"Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor.","volume":"80","author":"Broudy","year":"1992","journal-title":"Blood."},{"key":"2019111616403470900_B11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10428199309147354","article-title":"Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells.","volume":"10","author":"Kanakura","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"2019111616403470900_B12","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med."},{"key":"2019111616403470900_B13","first-page":"139","article-title":"Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.","volume":"295","author":"Buchdunger","year":"2000","journal-title":"J Pharmacol Exp Ther."},{"key":"2019111616403470900_B14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med."},{"key":"2019111616403470900_B15","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1056\/NEJM200104053441404","article-title":"Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastroinstestinal stromal tumor.","volume":"344","author":"Joensuu","year":"2001","journal-title":"N Engl J Med."},{"key":"2019111616403470900_B16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood."},{"key":"2019111616403470900_B17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V97.5.1413","article-title":"The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.","volume":"97","author":"Smolich","year":"2001","journal-title":"Blood."},{"key":"2019111616403470900_B18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res."},{"key":"2019111616403470900_B19","first-page":"76","article-title":"C-kit mutation screening in patients with acute myeloid leukaemia: adaptation of a Giemsa-stained bone-marrow smear DNA extraction technique.","volume":"58","author":"Court","year":"2001","journal-title":"Br J Biomed Sci."},{"key":"2019111616403470900_B20","first-page":"261","article-title":"Dominant negative and loss of function mutations of the c-kit (mast\/stem cell growth factor receptor) proto-oncogene in human piebaldism.","volume":"50","author":"Spritz","year":"1992","journal-title":"Am J Hum Genet."},{"key":"2019111616403470900_B21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1034\/j.1600-0609.2001.0430a.x","article-title":"Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts.","volume":"67","author":"Foss","year":"2001","journal-title":"Eur J Haematol."},{"key":"2019111616403470900_B22","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V96.6.2246","article-title":"CGP571 (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.","volume":"96","author":"Fang","year":"2000","journal-title":"Blood."},{"key":"2019111616403470900_B23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia.","volume":"105","author":"Gari","year":"1999","journal-title":"Br J Haematol."},{"key":"2019111616403470900_B24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.thj.6200168","article-title":"Amplification of a novel c-Kit activation mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutation for acute myeloid leukemia.","volume":"3","author":"Beghini","year":"2002","journal-title":"Hematol J."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/8\/2960\/1267858\/h80803002960.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/101\/8\/2960\/1267858\/h80803002960.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:40:46Z","timestamp":1573940446000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/101\/8\/2960\/16845\/Sustained-complete-hematologic-remission-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,15]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,4,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-05-1469","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2003,4,15]]}}}